Past and Future of Diagnosis and Therapy of Transmissible Spongiform Encephalopathy by Chih-Yuan Tseng & Jack Tuszynski
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
9 
Past and Future of Diagnosis and Therapy  
of Transmissible Spongiform Encephalopathy 
Chih-Yuan Tseng and Jack Tuszynski 
Department of Oncology, University of Alberta 
Edmonton, AB,  
Canada 
1. Introduction 
Transmissible spongiform encephalopathies (TSEs), also known as prion diseases, including 
Creutzfeldt-Jakob disease (CJD) in human, Bovine Spongiform Encephalopathy (BSE) in 
cow, and scrapie in sheep, represent diseases with complex and still poorly understood 
molecular mechanisms (Prusiner, 1998). The protein-only hypothesis postulates a possible 
pathogenic mechanism involving the prion protein. The helix rich normal prion protein 
(PrPC) is found to be infected by its -sheet rich abnormal proteinase K (PK)-resistant form, 
PrPSc, and is converted into PrPSc (Prusiner, 1998). This infection will lead to the 
aggregation of PrPSc-based amyloid fibrils that accumulate in the peripheral and invade to 
the central nervous system and damage neurons.  
In this chapter, we discuss current understanding of pathogenic mechanisms in this prion-
only hypothesis based disease in Section 2. This understanding then leads to the discussions 
of the past and present developments in both diagnosis and therapy for these diseases in 
Section 3. Based on the understanding of pathogenic mechanisms and current diagnosis and 
therapeutic strategies, we propose an alternative strategy. The proposal considers an 
aptamer-based theranostic approach to detect and prevent the aggregation of amyloid 
plaques in Section 4. Note that aptamer is defined as short nucleic acid sequences, and 
designed through Systematic Evolution of Ligands by EXponential enrichment (SELEX) 
(James, 2000). It is hoped that this proposal will open a novel research direction and 
eventually lead to a better diagnosis and treatment of prion diseases in the future.  
2. The infectivity of prion diseases  
Numerous models have been developed to provide better understanding of the 
pathogenesis of the prion diseases. One of models advanced is the template-assistance 
model (Prusiner, 1998; Horiuchi & Caughy, 1999; Tompa et al., 2002). This model assumed 
that PrPC, which is normally more stable than PrPSc in isolation, would in the presence of 
PrPSc convert to the latter via a transient catalytic interaction with it. The implication is that 
a dimer of PrPSc's is energetically more stable than a system of non-interacting PrPC and 
PrPSc. This was supported by Morrissey and Shakhnovich's computational analyses 
(Morrissey & Shakhnovich, 1999). When there are other PrPSc’s present, the initial 
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autocatalytic process would then lead to a propagation of PrPC to PrPSc conversion. 
Therefore, many studies have been focused on investigating possible mechanisms of this 
triggering event. For example, Zou and Cashman report in their studies that acidic 
environment increases the chance of triggering conversion (Zou & Cashman, 2002). Several 
groups have searched for the potential sites responsible for the conversion, referred to as hot 
spots, in PrPC (Guilbert, et al, 2000; Kuwata et al., 2007; Tseng et al., 2009). 
Furthermore, experimental evidences suggest that the infectivity of BSE cross-strains may 
associate with a host-independent molecule (Somerville, 2002). Gale showed that a 
phospholipid is most likely to be this molecule through the strain thermostability studies 
(Gale, 2006). Recent studies of prion diseases in membrane environments suggest that 
Phosphatidylserine (PS) is a molecule capable of altering amyloid aggregation pathways 
and increasing aggregation rates (Robinson & Pinheiro, 2010). This finding is further 
supported by the identification of the endosome recycling compartment as the potential 
conversion site (Marijanovic et al., 2009; Thellung et al., 2011). 
In addition to exploring pathogenic mechanisms, another fundamental issue is how PrPSc 
based amyloid aggregation leads to the development of clinical symptoms and 
neuropathology. Chiesa et al. have designed a series of experiments based on Tg(PG14) mice 
models to resolve this issue (Chiesa et al., 2000). They demonstrated that one of the most 
obvious symptoms in neuropathology is massive loss of cerebellar granule cells due to 
apoptosis. Apoptosis is a vital, highly regulated, natural process that contributes to the 
development and maintenance of human and animal cells and tissues (Kerr et al., 1972; 
Weinberg, 2007). Apoptosis plays multiple roles in the normal development of organisms 
extending from embryonic development to the maintenance of normal cell homeostasis 
(Reed & Tomaselli, 2000; Elmore, 2007; Rastogi et al., 2009). Chiesa et al.’s discovery is 
supported by a recent study by Thellung et al. (Thellung et al., 2011), in which SH-SY5Y 
human neuroblastoma cells were used. They observed that accumulation of human 
PrPSc90-231 in membrane triggers lysosome dependent apoptosis and leads to neuronal 
cells death.  
These insights seem open a route that differs from modern approaches as will be discussed 
below and which could lead to novel detection and “treatment” methods of prion diseases. 
However, before we propose this alternative solution, we first need to understand how 
modern approaches work including their advantages and shortcomings.  
3. Past and current developments of diagnosis and treatment of prion 
diseases 
3.1 Diagnosis 
According to the WHO manual for surveillance of human TSEs (WHO, 2003), current 
diagnosis methods can be categorized into two groups based on pathological characteristics 
of TSEs at microscopic and macroscopic levels. First, because of the diverse etiology of prion 
diseases in humans and animals, many studies have focused on the search for common 
mechanisms of these diseases at the molecular (microscopic) level in order to detect their 
onsets. The key question in this search is to ask if one can distinguish PrPSc from PrPC 
based on pathological changes and how this can be accomplished. The crux of the matter 
hinges on the conventional belief that specific prion protein types correlate with phenotypes 
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of the disease. Second, several pathological characteristics of TSEs at the brain (macroscopic) 
level are generally recognized, can one distinguish signals or patterns generated by diseased 
brains from those present in normal brains. The key to correct diagnosis of TSEs then 
depends on the specificity and sensitivity of sensors  
Regarding to the first group of diagnoses, three characteristics of PrPSc including prion 
protein gene (PRNP) codon 129 polymorphisms (Quadrio et al., 2011), Tyr-Tyr-Arg 
exposure (Paramithiotis et al., 2003) and over-expression of brain protein 14-3-3 (P14-3-3) 
(Hsich et al., 1996) were found to be distinctive from PrPC. Regarding to first characteristic, 
codon 129 was shown to be responsible for determining the variants of PK-resistant PrPSc in 
CJD (Parchi et al., 1996, 1999). Note that codon 129 encodes for two amino acids, methionine 
(M) and valine (V). A phenotypic influence in inherited prion diseases associated with 
codon 129 has been investigated and summarized in (Kovacs et al., 2002; Capellari et al., 
2011). Regarding to second characteristic, Paramithiotis et al. showed that the Tyr-Tyr-Arg 
motif in PrP, which is a hydrophilic-like fragment, will be exposed to solvent when PrPC is 
converted into PrPSc. Regarding the third characteristic, P14-3-3 has been studied because of 
its potential as a bio-marker (Hsich et al., 1996). Basically, they found the presence of 
proteins 130 and 131, which are P14-3-3 type proteins, in cerebrospinal fluid from patients 
with CJD and little amount in normal patients. This result has led to the development of 
P14-3-3 immunoassays to aid in the diagnosis of prion diseases. 
Regarding the second group, several noninvasive tools such as electroencephalography 
(EEG) and magnetic resonance imaging (MRI) have been investigated to detect abnormal 
onsets of prion diseases in brain besides biopsy. Tschampa et al. have shown that periodic 
sharp wave complexes appear in neuronal electric signals measured by non-invasive EEG in 
patients with CJD. These complexes are most likely the consequence of parvalbumin-
positive neurons being reduced in the majority of thalamic nuclei (Tschampa et al., 2002). 
Namely, the damage to these neurons determines the generation of this typical clinical 
feature of CJD. World Health Organization (WHO) has standardized a protocol using EEG 
in diagnosis in 1998 (WHO, 2003). For MRI-related methods such as fluid attenuation 
inversion recovery (FLAIR) and diffusion-weighted MRI imaging (DWMRI), these are still 
relatively new techniques that have been introduced (Appel et al., 2011). These methods are 
based on the detection of abnormal signals from the basal ganglia, thalamus and cortex of 
patients. However, since most studies have investigated using only small samples it is still 
impossible to firmly confirm the usefulness of MRI in this context. Nevertheless, it was 
shown that MRI may be able to better locate abnormal patterns in deep gray matter while 
EEG may be more sensitive in the cortex. Both methods may have a complementary role in 
diagnosing prion diseases. 
In summary, there are three tools commonly considered to aid in the diagnosis of prion 
diseases at present. Regarding codon 129 (genetic analysis), there are more and more studies 
that support the findings of a reproducible phenotypic spectrum of CJD variants and that 
the codon 129 genotype acts as the main determinant of the disease phenotype. Namely, 
DNA sequencing of the coding region of the PRNP may detect the onset of the disease. 
Regarding P14-3-3 (immunoassay), although it is not specific to prion diseases, it is a marker 
of neuronal damage and has been available in vivo. Regarding the periodic sharp wave 
complexes (EEG analysis), it indicates a footprint of neuronal electric signals from neurons 
damaged by PrPSc aggregation. It has been found that incorporation of non-invasive EEG 
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analysis and P14-3-3 detection increases the sensitivity of detection and improves diagnostic 
criteria (Zerr et al., 2000). Furthermore, Quadrio et al. suggest that conducting genetic 
analysis focusing on PRNP in addition to the combination of P14-3-3 detection and EEG 
analysis provides an extensive strategy to better diagnose prion diseases because these 
methods are sensitive to specific variants of PrP (Quadrio et al., 2011). Because the current 
molecular-based diagnoses hinge on the specificity and sensitivity of distinguishing 
between PrPC and PrPSc, the variants of PrP lower the success rate of these methods. 
Searching for more universal footprints of these variants will be one way to better detect the 
onset of prion diseases. Note that there are many other methods not mentioned here 
including in vivo biomarkers in blood and urine and tissue-based analysis which are 
currently under investigation (refer to (WHO, 2003; Quadrio et al., 2011) for more details). 
3.2 Treatments 
3.2.1 Rationale 
Although there are no effective therapies for prion diseases yet, one can still summarize the 
current strategies as being divided into three categories based on various concepts of 
choosing therapeutic targets. Note that the discussions below are based on the assumption 
that the blood-brain barrier penetration issue is overcome. Moreover, an additional issue in 
treating prion diseases, administration methods was shown by Doh-ura et al. (Doh-ura et 
al., 2004) to be equally crucial as designing better inhibitors. These authors have 
demonstrated intra-ventricular administration of pentosan polysulfate (PPS, an FDA 
approved drug originally designed for anti-malaria treatments) through an infusion device 
can inhibit PrPSc aggregation. However, based on our expertise in drug discovery, we will 
limit our discussion to addressing the issue of effective inhibitor design in this section.  
Based on the prion hypothesis, researchers in this field have focused on three targets, which 
include PrPC, PrPSc and PrPSc-producing cells. First, regarding the selection of PrPC as a 
target, Mallucci et al’s study provides strong evidence in support of this choice (Mallucci et 
al., 2007). They showed that when PrPc is depleted at an early stage of the disease in mouse, 
damaged neuronal functions are recovered. Furthermore, the recovery is independent of 
PrPSc aggregation, which implies novel mechanisms of neurotoxicity and therapeutic 
possibilities. Second, for choosing PrPSc as a target, the idea is simply to stop PrPSc 
aggregation. Many studies pointed out that PrPSc is replicated and accumulated in the 
lympho-reticular system during the initial stage of extra-cerebral prion infection (Mabbott & 
MacPherson, 2006). Furthermore, because Korth et al. discovered a unique epitope in PrPSc 
(Korth et al, 1997), this finding makes PrPSc a promising target to prevent prion infection at 
an early stage through immunotherapy. Third, for choosing PrPSc-producing cells as a 
target, the goal is to stop the infection in the peripheral nervous system and to prevent the 
plaque from being transmitted to the central nervous system. Several studies suggest 
dendritic cells as a potential target to inhibit neuronal invasion because of the role of 
dendritic cells in up-regulating follicular dendritic cells (FDCs), in which PrPSc are 
replicated and accumulated in diseased mice (Huang et al., 2002; Brown et al., 2009). 
Various bio-materials including antibodies, chemical compounds and aptamers have been 
investigated as inhibitors for these three targets. For example, targeting PrPC includes anti-
PrP antibody development (Fe´raudet-Tarisse et al., 2010) and PPS (Doh-ura et al., 2004) etc. 
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Targeting PrPSc includes anti-PrP monoclonal antibody development (Mab) IgM 
(Paramithiotis, 2003) and 6D11 (Sadowski, 2009) and RNA aptamer design (Weiss et al., 
1997; Proske et al., 2002; Rhie et al., 2003). For PrPSc-producing cells, cytotoxic T cells, 
antibody raised based on dendritic cells are used (Rosset et al. 2009). Although the results 
obtained from the immunotherapy focused on either PrPC, PrPSc or PrPSc-producing cells 
remain controversial, the immunotherapy is still a widely investigated strategy and has 
been shown to have an anti-prion effect in cellular and animal models (Paramithiotis et al., 
2003; Sadowski et al., 2009; Fe´raudet-Tarisse et al., 2010). Because of the controversial issues 
in immunotherapy, many other groups continue searching for novel small molecule 
inhibitors including those either mimicking negative inhibition of prion replication by 
Perrier et al. (Perrier et al., 2000) or those targeting protease-resistant PrP by Charvériat et al. 
(Charvériat et al., 2008). 
Since currently immunotherapy is the most developed and promising treatment, we will 
only focus on this modality in order to learn more about the key issues involved and to gain 
better understanding of the features of prion diseases revealed through these studies as 
discussed in the following sections. 
3.2.2 Immunotherapy  
Basically, immunotherapy hinges on inducing anti-PrP antibodies in appropriate hosts and 
utilizes these anti-PrP antibodies to activate the host’s immune system’s response against 
PrPSc aggregation. Several approaches of generating antibodies are employed including 
either bacterially-expressed full length PrP, PrP-PrP polyproteins, synthetic PrP peptides 
etc. However, studies have shown these approaches result in a low anti-PrP titer and 
immune-effects are moderate (Heppner & Aguzzi, 2004). 
Nevertheless, immunotherapy still attracts the attention of many investigators. While much 
effort has been made to determine more factors responsible for prion conversion as potential 
drug targets, as mentioned previously, even more work is focused on targeting either PrPC, 
PrPSc or PrPSc-producing cells. A strategy that applies anti-PrP antibodies directly against 
PrPC has been shown to delay PrPSc peripheral accumulation (Fe´raudet-Tarisse et al., 
2010). Fe´raudet-Tarisse et al. (2010) further studied pharmacokinetics and 
pharmacodynamics of several anti-PrP antibodies to examine their immunotherapeutic 
effects in mice. Another strategy in immunotherapy is to target PrPSc peripheral replication 
in the lympho-reticular system before the central nervous system (Bessen et al. 2009). The 
follicular dendritic cells are the major target of prion infection. Sadowski et al. showed that 
Mab 6D11 raised against PrPSc fibrils from brains of terminally ill CD-1 mice infected with 
139A strain (Kascsak et al, 1987) prevents infection of FDC-P1 cells and removes PrPSc from 
the infected FDC-P1/22L cell line (Sadowski et al., 2009). However, Sadowski et al. also 
showed that time-limited treatment, which is more practical from the clinical point of view, 
using Mab 6D11 is not capable of preventing prion diseases. This result is also supported by 
the findings of Fe´raudet-Tarisse et al. (Fe´raudet-Tarisse et al., 2010). Therefore, one can 
conclude that the currently available anti-PrP antibodies are likely to only temporarily 
control PrPSc aggregation. 
In summary, several issues hinder the practical implementation of immunotherapy in prion 
diseases. It includes a low anti-PrP antibody titer and moderate immuno-effects. 
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Furthermore, additional issues such as the expressed full length PrP approach are discussed 
below. First, the products failed to recognize the cell-surface PrPC, which is believed to 
directly associate with prion conversion, in wild type mice (Heppner & Aguzzi, 2004) and 
second, the full length antibodies when encountering the blood-brain barrier, are unable to 
cross it and enter into brain (Campana et al., 2009). The molecular mechanisms in the issue 
of low titer and moderate immuno-effects require more studies for better understanding. 
The latter issue may be resolved based on the work of Campana et al., in which they 
proposed a protocol to develop antibody fragments for prion diseases (Campana et al., 
2009).  
To develop a more promising immunotherapy for prion diseases in the future, it will require 
further investigations into various key areas. As shown in the works (Heppner & Aguzzi, 
2004; Sadowski et al., 2009; Fe´raudet-Tarisse et al., 2010), these key areas include 
understanding the mechanisms of antibody resistance, identification of better antibodies 
against either PrPC or PrPSc (or other immune effectors such as dendritic cells (Rosset et al. 
2009)) and designing proper administration methods (not addressed here) etc. 
4. Aptamer-based theranostic approach to targeting phosphatidylserine 
4.1 Logic 
In the diagnosis and treatment of prion diseases, as mentioned previously, two questions 
need to be answered, i.e.: (a) what are “good” factors that would allow detectors to 
distinguish between PrPC and PrPSc and (b) what are appropriate therapeutic targets. In 
diagnosis, Protein P14-3-3 was shown to be a marker for neuronal damage and its use in 
detecting the onset of prion diseases has been demonstrated in vivo (Hsich et al., 1996). The 
question emerges if there are any other markers one can utilize to detect neuronal damage 
due to PrPSc aggregation? In terms of therapy, we have previously stated that three targets, 
PrPC (Mallucci et al., 2007), PrPSc (Huang et al., 2002; Brown et al., 2009) and PrPSc-
producing cells (Bessen et al. 2009) are commonly considered as proper targets that could be 
used to prevent the disease. However, there are no effective prophylactic or therapeutic 
treatments available at present (Fe´raudet-Tarisse et al., 2010). Even for immunotherapy, its 
effects remain controversial (Heppner & Aguzzi, 2004). Since this controversial issue is yet 
to be resolved, we argue that targeting conversion factors rather than either PrPC, PrPSc, or 
PrPSc-producing cells may emerge as a viable strategy to avoid this problem and treat prion 
diseases. 
As discussed in Sec. 2, Gale has shown that PS is the host-independent molecule associated 
with enhancing PrPSc aggregation (Gale, 2006). Robinson and Pinheiro have recently 
reported that PSs alter amyloid aggregation pathways by increasing aggregation (Robinson 
& Pinheiro, 2010), which suggests an alternative approach for therapeutic treatment of prion 
diseases. Namely, we may be able to delay or even stop PrPSc aggregation by directly 
inhibiting the interactions between PSs and PrPSc amyloid.  
Furthermore, Chiesa et al and Thellung et al. have shown intracellular PrPSc aggregation in 
membranes triggers apoptosis (Chiesa et al, 2000; Thellung et al., 2011). Since we know that 
an early marker of apoptosis is the redistribution of PS between inner and outer plasma 
membranes (PS externalization) (Reutelingsperger et al., 1995; Blankenberg, 2009), PS 
externalization is specific to apoptotic cells with the exception of activated platelets and 
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erythrocytes. Therefore, it is an attractive target for apoptosis detection (Blankenberg, 2008, 
2009; Smrz et al., 2008) and as means of providing an early indication of the success or 
failure of therapy for prion diseases. 
4.2 Aptamer design 
Recently, aptamers have attracted great attention and may provide a viable alternative in 
the diagnosis and treatment of prion diseases (Weiss et al., 1997; Proske et al., 2002; Rhie et 
al., 2003). Aptamers are in many aspects, such as binding specificity and strong affinity, 
equivalent to antibodies. There are several advantages of using aptamers over antibodies. 
First, the selection of aptamers using SELEX can target any system while identification of 
antibodies depends on animal systems. Second, once an aptamer is selected, it can be easily 
synthesized and manipulated. 
Based on their characteristics, aptamers appear to be a viable material, other than antibodies, 
to be implemented as either inhibitors or detectors of cellular events such as apoptosis. 
Aptamers are selected through SELEX to bind to specific bio-molecular targets including 
small molecules, proteins, nucleic acids, phospholipids as well as complex structures such as 
cells, tissues, bacteria and other organisms. Because aptamers have strong and specific 
binding affinity through molecular recognition and low toxicity, they are generally 
recognized as having potential therapeutic and diagnostic clinical applications (Nimjee et 
al., 2005; James, 2000). SELEX consists of a number of rounds of in vitro selection in which 
the RNA/DNA pool is incubated with the binding target. In practice, multiple rounds of 
selection and expansion are required in SELEX before unique tightly binding sequences can 
be identified. Additionally, isolated aptamers will often need to be re-engineered to reduce 
their sequence length and impart additional favorable biological properties. These issues 
pose a challenge for the efficient identification of correct aptamers. 
Despite the issues involved in the use of SELEX, several groups have successfully identified 
RNA aptamers to bind specifically to either PrPC (Weiss et al., 1997; Proske et al., 2002) or 
PrPSc (Rhie et al., 2003). Proske et al. have utilized PrPC protein comprising amino acid 
residues 90-129, which belong to a short epitope (90-141) as the target. The resulting RNA 
aptamer has been shown to recognize the full-length PrPC and to reduce PrPSc formation in 
prion-infected neuroblastoma cells. On the other hand, Rhie et al. have selected RNA 
aptamers targeting scrapie-associated fibrils. They have shown an at least 10-fold higher 
binding affinity for PrPC. Although this aptamer has not been tested for its ability to inhibit 
the prion conversion in either cell lines or animal models, the studies in a cell-free model 
system do show the inhibition of the conversion due to the presence of this aptamer. 
Even though we cannot dismiss the applicability of the above two examples in prion 
diseases, the issues involving SELEX still impede practical implementations of aptamer 
structures in various directions in both diagnosis and therapeutics. We have developed an 
information-driven theoretical approach, called Entropic Fragment Based Aptamer design 
(EFBA), in order to resolve these issues and design aptamers based solely on the structural 
information regarding molecular targets. Basically, our approach is based on a seed-and-
grow strategy to determine the aptamer that has the highest probability to interact with the 
target of interest. Details of the approach and its validation are discussed in (Tseng et al., 
2011). 
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Because of the molecular characteristics of aptamers and our validated aptamer design 
algorithm, we can apply the algorithm to computationally design aptamer-based 
theranostic agents that can specifically bind to any targets that are associated with either 
prion conversion or PrPSc aggregation. Thereafter, we can computationally and 
experimentally investigate its binding properties and apply the results to improve the 
designed sequence. 
4.3 Aptamer-based theranostic approach targeting PS 
4.3.1 Strategy 
As we know, PS is shown to increase PrPSc aggregation, which is independent of the host, 
and PrPSc aggregation triggers apoptosis. Furthermore, when apoptosis is initiated, an early 
indication of this process is PS externalization. Therefore, we propose to design an aptamer 
simply targeting PS to inhibit interactions between PrPSc and PS. The inhibition may also 
delay accumulation. Besides, we can monitor the changes of PS externalization to not only 
detect the onset of the disease but also to estimate therapeutic effects.  
The advance of aptamer design of our algorithm allows us to computationally design an 
aptamer-based theranostic agent aimed at prion diseases. The application of aptamers will 
likely be free from difficulties of using other materials such as a well-studied apoptotic 
probe, annexin V, a small peptide (Blankenberg, 2009). For example, annexin V has a high 
uptake in normal tissues, especially liver and kidney, a long biological half-life in non-
target tissues, a high radiation burden for 111In and 124I analogs and laborious 
radiochemistry for the labeling (Boersma et al., 2005). Therefore, an aptamer attached with 
a fluorescence tag that specifically binds to PS can both inhibit the interactions between 
PrPSc aggregation and PS and detect the changes of PS externalization at the same time 
using fluorescence imaging.  
In the following, we will only demonstrate the application of our aptamer design algorithm 
in designing a DNA aptamer to bind specifically to PS. Furthermore, wet lab investigations 
in both imaging properties and therapeutic effects will not be presented here because of 
resource limitations at present.  
4.3.2 The PS DNA-aptamer 
In our earlier work (Tseng et al., 2011), the design of a PS aptamer has been briefly 
addressed. Basically, we start with the molecular model of PS, which was manually 
constructed using the MOLDEN program (Schaftenaar & Noordik, 2000). The resulting 
structure was then minimized with the GAMESS-US (Schmidt et al., 1993) program using 
the AM1 semi-empirical method (Dewar & Dieter, 1986; Dewar et al., 1985). The PS structure 
was further equilibrated using molecular dynamics simulation for 1 ns for DNA aptamer 
design. Two top sequences, namely 5’-AAAAGA-3’ (PS-aptamer I) and AAAGAC (PS-
aptamer II), were selected from our design for experimental binding assays and in silico 
experiments (in silico results are not shown here). The structure of the PS-aptamer I in new 
ribbons format and the potential location of its binding site are shown in the left panel of 
Fig. 1. Note that the aptamer structure has not been energy equilibrated yet. 
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Fig. 1. The tertiary structure (on the left) of the designed PS-aptamer I generated using VMD 
(Humphrey et al., 1996) and the two-dimensional structure (on the right) of PS are shown. 
Note adenine is colored by blue and guanine is red. 
Two liposomes were prepared in order to study both the designed PS aptamer binding 
affinity and specificity. The first one uses DPPC and DPPS at a 10:1 DPPC/DPPS molar ratio 
and the second one uses DPPC alone. In both cases cholesterol exists at the 
DPPC/cholesterol molar ratio of 2:1. The latter served as a control without PS available for 
binding. The results are shown in Fig. 2. The low fluorescent level shown in the right-hand 
panel indicates that the PS-aptamer II binds either poorly or not at all to DPPC. Conversely, 
the left–hand panel shows a relatively high fluorescence level while DPPS is present. It 
suggests that both DNA aptamers bind specifically to DPPS. Second, although both DNA 
aptamers bind to DPPS, the results show that the PS-aptamer II has a higher fluorescence 
level than the PS-aptamer I when the concentrations of DNA aptamers are increased beyond 
0.165 nmol. This suggests that the PS-aptamer II has a relatively better or stronger binding 
affinity than PS-aptamer I. 
Since the fluorescence studies did not show any saturation point for both aptamers, it is 
definitely required to further re-engineer this PS aptamer template to enhance its binding 
affinity before one can consider implementing it to become a theranostic agent. 
Furthermore, more studies in model systems and cell lines, are required to further 
investigate the theranostic effects of this aptamer. Nevertheless, given an appropriate drug 
delivery technique such as the exosome-based drug delivery technique (Alvarez-Erviti et al., 
2011), which has the ability to carry therapeutic agents including nucleic acid across the 
blood-brain-barrier, to deliver PS aptamer into cells, it is likely that this PS aptamer-based 
theranostic agent will open new possibilities in the development of a successful therapy for 
prion diseases. 
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Fig. 2. Fluorescence (FL) measured in relative fluorescence units (RFU) versus DNA aptamer 
concentration. Left panel: selective binding of two designed DNA aptamers with liposomes 
containing PS. Right panel: low non-specific binding of designed DNA aptamer with 
liposome containing only PC. 
5. Conclusions 
We have reviewed current understanding of infectivity of prion diseases and recent 
developments in the area of diagnosis and therapeutic strategies involving various types of 
biochemical and chemical agents. In particular, we discussed the advantages and challenges 
involved in three tools, genetic (codon 129), P14-3-3 in the cerebrospinal fluid and EEG 
analysis, in diagnosis and a widely investigated treatment, immunotherapy. Based on these 
insights into the search for a detector to diagnose the onset of prion diseases and treatments 
aimed at either stopping prion conversion or PrPSc aggregation, a prion conversion factor, 
PS, has recently attracted our attention. In those studies, PS has been shown to increase 
PrPSc aggregation. This aggregation then activates neuronal cell apoptosis, which in turn 
triggers PS externalization as an early marker. We argue that these two discoveries may 
suggest a potential theranostic target. 
An aptamer-based theranostic approach targeting PS is proposed here. Based on our 
recently proposed aptamer design algorithm, a promising result in designing a specific PS 
binding aptamer is demonstrated. A series of wet lab studies will be designed to validate 
and implement this proposal including both imaging of apoptosis events and inhibition of 
PrPSc aggregation. Finally, given this PS DNA aptamer template, we hope this proposal will 
trigger a ripple effect in the research community and lead to a solution which will assist us 
in diagnosing and preventing prion diseases. 
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